%; P <.001) ( Figure 1B ). Table 1. Patient Characteristics Figure 1. Treads of initial treatment in patients with metastatic (A) esophageal and (B) gastric cancers. a P value represents the significance test for the linear trend
Search Results
Page:12
Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven
Tiffany H. Svahn, Joyce C. Niland, Robert W. Carlson, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Stephen B. Edge, Anne F. Schott, Michael A. Bookman, and Jane C. Weeks
After the first report of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, adjuvant aromatase inhibitor use increased rapidly among National Comprehensive Cancer Network member institutions. Increased aromatase inhibitor use was associated with older age, vascular disease, overexpression of human epidermal growth factor receptor 2 (HER2), or more advanced stage, and substantial variation was seen among institutions. This article examines adjuvant endocrine therapy in postmenopausal women after the first report of the trial, identifies temporal relationships in aromatase inhibitor use, and examines characteristics associated with choice of endocrine therapy among 4044 postmenopausal patients with hormone receptor–positive nonmetastatic breast cancer presenting from July 1997 to December 2004. Multivariable logistic regression analysis examined temporal associations and characteristics associated with aromatase inhibitor use. Time-trend analysis showed increased aromatase inhibitor and decreased tamoxifen use after release of ATAC results (P < .0001). In multivariable regression analysis, institution (P <. 0001), vascular disease (P <. 0001), age (P = .0002), stage (P = .0002), and HER2 status (P = .0009) independently predicted aromatase inhibitor use. Institutional rates of use ranged from 15% to 66%. Adjuvant aromatase inhibitor use increased after the first report of ATAC, with this increase associated with older age, vascular disease, overexpression of HER2, or more advanced stage. Substantial variation was seen among institutions.
Xiang Gao, Amanda R. Kahl, Paolo Goffredo, Albert Y. Lin, Praveen Vikas, Imran Hassan, and Mary E. Charlton
at: https://seer.cancer.gov/statfacts/html/colorect.html 2. Hu CY , Bailey CE , You YN , . Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival . JAMA Surg 2015 ; 150 : 245 – 251
Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban, and Yaacov Richard Lawrence
White RR . Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the Surveillance, Epidemiology, and End Results registry from 1988 to 2008 . Pancreas 2013 ; 42 : 1157 – 1163 . 7. Tas
Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon, and Quoc-Dien Trinh
racial disparities in EOL care; broadly speaking, black patients are less likely to undergo therapeutic and diagnostic interventions, and are more likely to receive high-intensity EOL care. Our trend analysis shows that the prevalence of high
Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen, and Li Zhu
breast cancer: a propensity-adjusted, population-based SEER trend analysis . Ann Surg 2016 ; 263 : 1188 – 1198 . 26943635 10.1097/SLA.0000000000001302 25. Lane WO , Thomas SM , Blitzblau RC , . Surgical resection of the primary tumor in women
Puneeth Iyengar and Robert D. Timmerman
. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis . J Clin Oncol 2010 ; 28 : 5153 – 5159 . 31 Grills IS Mangona VS Welsh R . Outcomes
Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu
number of SRS facilities increased yearly from 285 (31.2%) in 2004 to 515 (50.4%) in 2014 ( Figure 3 ). Survival Trends Analysis Among the 67,448 patients in the survival analysis, 1-year actuarial overall survival was 26.6% for the entire
survival benefit, although this difference was not statistically significant ( P= .10). On subset analysis of studies using OS as the primary end point, no difference was seen in relative survival benefit ( P= .22). In a trends analysis of the relative
Margaret A. Tempero, Mokenge P. Malafa, Stephen W. Behrman, Al B. Benson III, Ephraim S. Casper, E. Gabriela Chiorean, Vincent Chung, Steven J. Cohen, Brian Czito, Anitra Engebretson, Mary Feng, William G. Hawkins, Joseph Herman, John P. Hoffman, Andrew Ko, Srinadh Komanduri, Albert Koong, Andrew M. Lowy, Wen Wee Ma, Nipun B. Merchant, Sean J. Mulvihill, Peter Muscarella II, Eric K. Nakakura, Jorge Obando, Martha B. Pitman, Sushanth Reddy, Aaron R. Sasson, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns, and Deborah A. Freedman-Cass
. 5. StatBite . U.S. pancreatic cancer rates . J Natl Cancer Inst 2010 ; 102 : 1822 . 6. Worni M Guller U White RR . Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the
Page:12
